Omega-3 Index Interpretation by Decade of Life

What the index measures

The index is red-blood-cell EPA plus DHA as a percentage of total red-blood-cell fatty acids [1]. Red-cell composition reflects long-term intake, not one meal [1]. In 10 cohorts the mean was 6.1% (SD 2.1), and each 1-SD higher index was associated with a hazard ratio of 0.85 for coronary heart disease mortality (95% CI 0.80 to 0.91) [2]. Moving from an index of 4% to 8% was estimated to correspond to about 30% lower fatal coronary heart disease risk [2]. These are observational associations, not proof that raising the number prevents events [1][4].

Where the cut-offs come from

The 2004 paper that proposed the index linked 8% or higher with the greatest cardioprotection and 4% or lower with the least [1]. The 2017 analysis of 10 cohorts concluded that its findings supported below 4% and above 8% as reasonable targets, and described 8% to 12% as the lower-risk range [2]. Both are cohort-based associations with coronary heart disease death. Randomized trials of omega-3 supplements have mostly not reduced cardiovascular events, so the cut-offs are not shown to be treatment targets [4]. Neither paper reports age-specific ranges [1][2].

Supplement dose and atrial fibrillation

The supplement dose, rather than the index boundary, is where a clear safety signal exists.

A 2021 meta-analysis of 7 cardiovascular outcome trials with 81,210 patients found more atrial fibrillation with marine omega-3 supplements (HR 1.25, 95% CI 1.07 to 1.46) [3]. The signal was larger in trials testing more than 1 g/day (HR 1.49, 95% CI 1.04 to 2.15) than in trials testing 1 g/day or less (HR 1.12, 95% CI 1.03 to 1.22) [3].

What trial data add

Outcome trials tested fixed doses, not index targets. REDUCE-IT gave prescription icosapent ethyl 4 g/day to 8,179 statin-treated patients with raised triglycerides and established cardiovascular disease or diabetes plus risk factors, and found a primary composite of 17.2% versus 22.0% (HR 0.75, 95% CI 0.68 to 0.83) [5]. VITAL tested 1 g/day of marine omega-3 in 25,871 adults not selected for high risk and did not significantly reduce major cardiovascular events (HR 0.92, 95% CI 0.80 to 1.06) [6]. STRENGTH tested 4 g/day of omega-3 carboxylic acids against corn oil in 13,078 high-risk, statin-treated patients and found no benefit (HR 0.99, 95% CI 0.90 to 1.09) [7].

Reading a result

A result at or below 4% is the higher-risk end of the original scheme; at or above 8% is the lower-risk end [1]. The 6.1% figure is the mean across the 10 studied cohorts; it is not a personal target [2]. If the result is being used to judge a supplement, the EPA and DHA amount on the label matters more than the total fish oil milligrams; capsule content varies, and trial doses ranged from 1 g/day to 4 g/day [5][6][7].